VBP15, a novel dissociative steroid compound, reduces NFκB-induced expression of inflammatory cytokines in vitro and symptoms of murine trinitrobenzene sulfonic acid-induced colitis.
A novel dissociative steroid VBP15 reduces MUC5AC gene expression in airway epithelial cells but lacks the GRE mediated transcriptional properties of dexamethasone.
VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects.
VBP15, a glucocorticoid analogue, is effective at reducing allergic lung inflammation in mice.
VBP15: preclinical characterisation of a novel anti-inflammatory delta 9,11 steroid.
Large-scale serum protein biomarker discovery in Duchenne muscular dystophy